Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

Treatment of polycythemia vera with imatinib mesylate.

Silver RT, Bourla MH, Vandris K, Fruchtman S, Spivak JL, Feldman EJ, Salvado AJ.

Leuk Res. 2012 Feb;36(2):156-62. doi: 10.1016/j.leukres.2011.09.001. Epub 2011 Oct 7.

PMID:
21983176
[PubMed - indexed for MEDLINE]
2.

Phase II open label trial of imatinib in polycythemia rubra vera.

Jones CM, Dickinson TM, Salvado A.

Int J Hematol. 2008 Dec;88(5):489-94. doi: 10.1007/s12185-008-0193-1. Epub 2008 Nov 15.

PMID:
19009241
[PubMed - indexed for MEDLINE]
3.

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.

Cortes J, Giles F, O'Brien S, Thomas D, Albitar M, Rios MB, Talpaz M, Garcia-Manero G, Faderl S, Letvak L, Salvado A, Kantarjian H.

Cancer. 2003 Jun 1;97(11):2760-6.

PMID:
12767088
[PubMed - indexed for MEDLINE]
Free Article
4.

Effects of imatinib mesylate in patients with polycythemia vera: results of a phase II study.

Merx K, Fabarius A, Erben P, Griesshammer M, Reiter A, Hofmann WK, Hehlmann R, Hochhaus A, Lengfelder E.

Ann Hematol. 2013 Jul;92(7):907-15. doi: 10.1007/s00277-013-1725-1. Epub 2013 Mar 24.

PMID:
23525684
[PubMed - indexed for MEDLINE]
5.

Long term follow-up of Polycythemia Vera patients treated with imatinib mesylate.

Michael Jones C.

Leuk Res. 2012 Jul;36(7):815-6. doi: 10.1016/j.leukres.2012.03.011. Epub 2012 Apr 5. No abstract available.

PMID:
22483066
[PubMed - indexed for MEDLINE]
6.

Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate.

Silver RT.

Curr Hematol Malig Rep. 2007 Feb;2(1):43-6. doi: 10.1007/s11899-007-0006-2. Review.

PMID:
20425387
[PubMed - indexed for MEDLINE]
7.

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera.

Silver RT.

Leukemia. 2003 Jun;17(6):1186-7. No abstract available.

PMID:
12764388
[PubMed - indexed for MEDLINE]
8.

Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate.

Silver RT.

Curr Hematol Rep. 2005 May;4(3):235-7. Review.

PMID:
15865878
[PubMed - indexed for MEDLINE]
9.

Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.

Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C.

Leuk Res. 2008 Dec;32(12):1830-6. doi: 10.1016/j.leukres.2008.04.026. Epub 2008 Jun 20.

PMID:
18571721
[PubMed - indexed for MEDLINE]
10.

Polycythemia vera responds to imatinib mesylate.

Jones CM, Dickinson TM.

Am J Med Sci. 2003 Mar;325(3):149-52.

PMID:
12640290
[PubMed - indexed for MEDLINE]
11.

Therapeutic options for essential thrombocythemia and polycythemia vera.

Solberg LA Jr.

Semin Oncol. 2002 Jun;29(3 Suppl 10):10-5. Review.

PMID:
12096352
[PubMed - indexed for MEDLINE]
12.

Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population.

Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, Luo Y, Tan Y, Shi J, Xie W, Ye X, Cai Z, Lin M, Huang H.

Int J Hematol. 2009 May;89(4):445-51. doi: 10.1007/s12185-009-0292-7. Epub 2009 Apr 7.

PMID:
19350352
[PubMed - indexed for MEDLINE]
13.

Imatinib mesylate in idiopathic and postpolycythemic myelofibrosis.

Hasselbalch HC, Bjerrum OW, Jensen BA, Clausen NT, Hansen PB, Birgens H, Therkildsen MH, Ralfkiaer E.

Am J Hematol. 2003 Dec;74(4):238-42.

PMID:
14635203
[PubMed - indexed for MEDLINE]
14.

Prognostic factors associated with complete cytogenetic response in patients with chronic myelogenous leukemia on imatinib mesylate therapy.

Cojbasić I, Macukanović-Golubović L.

Srp Arh Celok Lek. 2010 May-Jun;138(5-6):305-8.

PMID:
20607973
[PubMed - indexed for MEDLINE]
15.

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS.

Eur J Cancer. 2003 Sep;39(14):2006-11.

PMID:
12957454
[PubMed - indexed for MEDLINE]
16.

New drugs in essential thrombocythemia and polycythemia vera.

Tefferi A, Elliott MA, Solberg LA Jr, Silverstein MN.

Blood Rev. 1997 Mar;11(1):1-7. Review.

PMID:
9218101
[PubMed - indexed for MEDLINE]
17.

Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro.

Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K.

Blood. 2003 Sep 15;102(6):2240-2. Epub 2003 May 22.

PMID:
12763928
[PubMed - indexed for MEDLINE]
Free Article
18.

Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.

Kantarjian HM, O'Brien S, Cortes JE, Smith TL, Rios MB, Shan J, Yang Y, Giles FJ, Thomas DA, Faderl S, Garcia-Manero G, Jeha S, Wierda W, Issa JP, Kornblau SM, Keating M, Resta D, Capdeville R, Talpaz M.

Clin Cancer Res. 2002 Jul;8(7):2167-76.

PMID:
12114417
[PubMed - indexed for MEDLINE]
Free Article
19.

Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.

Gilbert HS.

Cancer. 1998 Sep 15;83(6):1205-13.

PMID:
9740087
[PubMed - indexed for MEDLINE]
20.

Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha.

Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, Hochhaus A, Oscier D, Metzgeroth G, Lengfelder E, Reiter A, Chase AJ, Cross NC.

Blood. 2006 Apr 15;107(8):3339-41. Epub 2005 Dec 13.

PMID:
16352805
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk